What was the impact of the Guidant acquisition on Abbott's financials?

The acquisition of Guidant’s vascular intervention and endovascular solutions businesses for approximately $4.1 billion significantly boosted the Vascular Products segment, leading to a 480.1% increase in sales for the third quarter and a 293.3% increase for the first nine months of 2006 compared to the prior year. This acquisition also contributed to increased R&D and SG&A expenses, as well as a substantial increase in goodwill and acquired intangible assets on the balance sheet.

How did the company's profitability change in this period?

Abbott demonstrated improved profitability, with its gross profit margin increasing to 57.1% for the third quarter of 2006 from 50.3% in the same period of 2005. This improvement was driven by a favorable product mix, particularly due to reduced sales of lower-margin Boehringer Ingelheim products, and operational efficiencies. However, increased R&D and SG&A expenses related to the Guidant acquisition and share-based compensation slightly impacted operating earnings.

What is the significance of the announced acquisition of Kos Pharmaceuticals?

The announced acquisition of Kos Pharmaceuticals for approximately $3.7 billion is a significant strategic move aimed at expanding Abbott's presence in specialty pharmaceuticals, focusing on chronic cardiovascular, metabolic, and respiratory diseases. This acquisition signals Abbott's commitment to growth through strategic M&A and will be financed with debt, further impacting the company's capital structure.

What are the main drivers behind the increase in Research and Development (R&D) expenses?

R&D expenses saw a substantial increase of 37.6% in the third quarter and 24.7% for the first nine months of 2006. Key drivers include the costs associated with the Guidant acquisition, increased spending to support pipeline programs (including further development of Humira and other late-stage projects), and the accounting impact of share-based compensation. The decision to discontinue the commercial development of the ZoMaxx drug-eluting stent also contributed to these expenses.

ABT 10-Q Quarterly Report Q3 FY2006 — Revenue, Net Income, EPS

Summary

Abbott Laboratories reported solid performance for the nine months ended September 30, 2006, with Net Sales of $16.26 billion. While total Net Sales saw a slight decrease of 0.2% compared to the prior year's nine months, excluding certain product sales impacted by an amended distribution agreement, the company achieved a healthy 10.5% growth, highlighting underlying operational strength. The third quarter of 2006 demonstrated a 3.5% increase in Net Sales year-over-year, reaching $5.57 billion, with a notable 15.0% growth when adjusted for specific product sales. The company significantly bolstered its Vascular Products segment through the acquisition of Guidant’s vascular intervention and endovascular solutions businesses for approximately $4.1 billion. This strategic move is reflected in the substantial revenue growth within this segment. Despite increased operating costs, including significant R&D investment and administrative expenses, Abbott maintained a strong gross profit margin of 57.1% for the third quarter, an improvement from 50.3% in the prior year, driven by favorable product mix and operational efficiencies. The company also announced a pending acquisition of Kos Pharmaceuticals for approximately $3.7 billion, signaling continued strategic investment in growth areas.

Key Highlights

1Net Sales for the nine months ended September 30, 2006, were $16.26 billion, with a 10.5% increase excluding specific BI products.
2Third quarter Net Sales reached $5.57 billion, up 3.5% year-over-year (15.0% excluding BI products).
3Acquisition of Guidant's vascular businesses for $4.1 billion significantly boosted the Vascular Products segment revenue.
4Gross profit margin improved to 57.1% in Q3 2006 from 50.3% in Q3 2005, indicating improved profitability and product mix.
5Research and Development expenses increased by 37.6% in Q3 2006, reflecting investment in pipeline programs and the Guidant acquisition.
6The company announced its intent to acquire Kos Pharmaceuticals for approximately $3.7 billion, indicating strategic growth initiatives.
7Earnings Per Share (Diluted) for the nine months was $1.43, a decrease from $1.53 in the prior year, impacted by various factors including acquisition-related expenses.

ABBOTT LABORATORIES Quarterly Report for Q3 Ended Sep 30, 2006

Summary

Key Highlights

Frequently Asked Questions